This is a working overview of gastric juice protein, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-10. Anything still debated is marked as such rather than presented as settled.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Below about 100 °C, volatiles, including some water, evaporate. Heat-sensitive substances, such as vitamin C and proteins, may partially change or decompose already at this stage. At about 100 °C or slightly higher, any remaining water that is merely absorbed in the material is driven off. This process consumes a lot of energy, so the temperature may stop rising until all water has evaporated. Water trapped in crystal structure of hydrates may come off at somewhat higher temperatures. Some solid substances, like fats, waxes, and sugars, may melt and separate. Between 100 and 500 °C, many common organic molecules break down. Most sugars start decomposing at 160–180 °C. Cellulose, a major component of wood, paper, and cotton fabrics, decomposes at about 350 °C. Lignin, another major wood component, starts decomposing at about 350 °C, but continues releasing volatile products up to 500 °C. The decomposition products usually include water, carbon monoxide CO and/or carbon dioxide CO2, as well as a large number of organic compounds. Gases and volatile products leave the sample, and some of them may condense again as smoke. Generally, this process also absorbs energy. Some volatiles may ignite and burn, creating a visible flame. The non-volatile residues typically become richer in carbon and form large disordered molecules, with colors ranging between brown and black. At this point the matter is said to have been "charred" or "carbonized".
Commission D2: Refrigerated Transport The IIR's Commission D2 on Refrigerated Transport is extremely active. In addition to the IIR's four-yearly congress, Commission D2 participates in the IIR Conference on Sustainability and the Cold Chain, held out of synchronisation with the congress. Every year, Commission D2 CERTE test engineers meet in a European country to discuss refrigerated transport technology and testing issues. This group subsequently advises the United Nations working party on transport of perishable foodstuffs held each year in Geneva. Commission D2 is currently addressing the “Cold Chain for Pharmaceutical Products” and will add this to regular transport discussion and advisory topics. Commission D2 also helps to produce Informatory Notes to assist in areas of technical or regulatory difficulty. The IIR is recognised, for its contributions to refrigerated transport, particularly through the work of its Commission D2. The commission's research addresses food waste reduction and emissions mitigation.
=== Research === In 2013, Rocky De Nys and his team at JCU along with CSIRO performed in vitro tests on 30 tropical macroalgae species using an artificial cow stomach. Dried seaweed biomass was mixed in with low quality roughage and combined with rumen fluid. Temperature and pH were then maintained to accurately simulate the fermentation process that occurs within ruminant stomachs during digestion. The total volume and concentrations of produced gases were measured for each sample at 12-hour intervals over a 72-hour period. All seaweed species were shown to reduce methane emissions in some capacity with a 50% average reduction. However this required dosages as much as 20% of dietary intake. This was problematic as the high concentrations required would most likely cause digestion issues for livestock by reducing the volume of volatile fatty acids. Asparagopsis taxiformis proved the most effective with a measured methane reduction of 98.9%. Dictyota was the second most effective seaweed with a measured methane reduction of 92%. The results of this experiment provided sufficient evidence for CSIRO to select Asparagopsis as the main ingredient in livestock feed. In 2014, a patent on a method for reducing total gas production and/or methane production in ruminants (such as sheep and cattle) was registered by CSIRO, MLA and JCU. De Nys and Kinley expanded upon the experiment in 2015 with the goal of finding an ideal dosage of Asparagopsis. The aim was to maximise methane reduction without compromising enteric health.
== Function == Peptide deformylase removes the formyl group from the N terminus of nascent polypeptides as they are synthesized by the ribosome. The function of peptide deformylase can be described by the following equation, where formyl-L-methionyl peptide and water react under the formation of formate and methionyl peptide:
== Amateur career == Epstein played for the baseball and football teams while attending Fairfax High School in Los Angeles, graduating in 1961. He was named to the baseball second team on the All-Western League Team two years in a row, by the Helms Athletic Foundation's All-Southern California Board of Athletics. He played quarterback and fullback on the football team. Epstein attended the University of California-Berkeley on a football scholarship, playing as a running back in 1962, under future NFL Hall of Fame coach Marv Levy and alongside future NFL quarterback Craig Morton. He was recruited to Berkeley by future NFL Hall of Fame coach Bill Walsh. He majored in social psychology and eventually played college baseball for the California Golden Bears, graduating in 1964. Although his .375 batting average in 1963 led to a contract offer by the Los Angeles Dodgers, he decided to finish college. The following year, he batted .384 as a senior and was named an All-American. His .381 career average is a school record. He represented the United States in baseball at the 1964 Summer Olympics as a demonstration sport in Tokyo. In 2023, Epstein was inducted into the California Athletics Hall of Fame.
Sources: en.wikipedia.org
Edema collection of fluid in the tissues of a part of the body. Diabetics often have edemic feet due to the impaired circulation in them. Electromyography EMG Test used to diagnose neuropathy and check for nerve damage. It uses electrodes to measure speed of nerve signal transmission. Damaged nerves have characteristic changes in transmission. Endocrine glands several glands and tissues which secrete signaling chemicals (almost always in very very small quantities) which control the function of other tissues. Insulin is produced by the endocrine part of the pancreas (i.e., beta cells) and is the primary hormone controlling metabolism. Endocrinologist a physician with special training in the operation and diseases of the endocrine system (i.e., the endocrine glands and tissues). Endogenous Grown or made inside the body. Insulin made by a person's own pancreas is endogenous insulin. Insulin that is supplied from outside the body (i.e., injected or otherwise supplied) is exogenous. End-stage renal disease (ESRD) The final phase of many kidney diseases; treated by dialysis or kidney transplantation. See also: Dialysis; nephropathy. Enzymes proteins which have the effect of greatly increasing the reaction rate of specific chemical reactions. Reaction rates are controlled by activation energies specific to particular reactions, and enzymes have the effect of lowering the activation energy. In general enzymes are chemicals which are not consumed by the reaction. In that sense, they are catalysts. Epidemiology the study of the transmission of diseases.
The king brown snake (Pseudechis australis) is a species of highly venomous snake of the family Elapidae, native to northern, western, and Central Australia. The king brown snake is the largest terrestrial venomous snake in Australia. Despite its common name, it is a member of the genus Pseudechis (black snakes) and only distantly related to true brown snakes. Its alternative common name is the mulga snake, although it lives in many habitats apart from mulga. First described by English zoologist John Edward Gray in 1842, it is a robust snake up to 3.3 m (11 ft) long. It is variable in appearance, with individuals from northern Australia having tan upper parts, while those from southern Australia are dark brown to blackish. Sometimes, it is seen in a reddish-green texture. The dorsal scales are two-toned, sometimes giving the snake a patterned appearance. Its underside is cream or white, often with orange splotches. The species is oviparous. The snake is considered to be a least-concern species according to the International Union for Conservation of Nature, though may have declined with the spread of the cane toad. Its venom is not as potent as those of Australia's other dangerous snakes, but can still cause severe effects if delivered in large enough quantities. Its main effect is on striated muscle tissue, causing paralysis from muscle damage, and also commonly affects blood clotting (coagulopathy). Often, extensive pain and swelling occur, rarely with necrosis, at the bite site. Deaths from its bites have been recorded, with the most recent being in 1969.
=== Natural occurrence === Earth has retained all of the noble gases that were present at its formation except helium. Krypton's concentration in the atmosphere is about 1 ppm. It can be extracted from liquid air by fractional distillation. The amount of krypton in space is uncertain, because measurement is derived from meteoric activity and solar winds. The first measurements suggest an abundance of krypton in space.
=== Venom === Rattlesnake venom is hemotoxic, destroying tissue, causing necrosis and coagulopathy (disrupted blood clotting). In the U.S., the tiger rattlesnake (C. tigris) and some varieties of the Mojave rattlesnake (C. scutulatus) also have a presynaptic neurotoxic venom component known as Mojave type A toxin, which can cause severe paralysis. However, most North American rattlesnakes are not neurotoxic. Although it has a comparatively low venom yield, the venom toxicity of C. tigris is considered to be among the highest of all rattlesnake venoms, and among the highest of all snakes in the Western Hemisphere based on LD50 studies conducted on laboratory mice. C. scutulatus is also widely regarded as producing one of the most toxic snake venoms in the Americas, based on LD50 studies in laboratory mice. Rattlesnake venom is a mixture of five to fifteen enzymes, various metal ions, biogenic amines, lipids, free amino acids, proteins, and polypeptides. More specifically, there are three main families of toxins in rattlesnakes: phospholipases A2 (PLA2s), snake venom metalloproteinases (SVMPs), and snake venom serine proteinases (SVSPs). It contains components meant to immobilize and disable the prey, as well as digestive enzymes, which break down tissue to prepare for later ingestion. The venom is very stable, and retains its toxicity for many years in storage. Snake venom, in general, has a complex and ongoing evolutionary process, and rattlesnake venom is no different. The primary mechanisms of evolution are both gene duplication and gene loss events.
Sources: en.wikipedia.org
In 2011, the FDA approved a phase I trial that used telemonitoring, also known as remote patient monitoring, to collect biometric data in patients' homes and transmit it electronically to the trial database. This technology provides many more data points and is far more convenient for patients, because they have fewer visits to trial sites. As noted below, decentralized clinical trials are those that do not require patients' physical presence at a site, and instead rely largely on digital health data collection, digital informed consent processes, and so on.
=== Functions of inhibitors === In many organisms, inhibitors may act as part of a feedback mechanism. If an enzyme produces too much of one substance in the organism, that substance may act as an inhibitor for the enzyme at the beginning of the pathway that produces it, causing production of the substance to slow down or stop when there is sufficient amount. This is a form of negative feedback. Major metabolic pathways such as the citric acid cycle make use of this mechanism. Since inhibitors modulate the function of enzymes they are often used as drugs. Many such drugs are reversible competitive inhibitors that resemble the enzyme's native substrate, similar to methotrexate above; other well-known examples include statins used to treat high cholesterol, and protease inhibitors used to treat retroviral infections such as HIV. A common example of an irreversible inhibitor that is used as a drug is aspirin, which inhibits the COX-1 and COX-2 enzymes that produce the inflammation messenger prostaglandin. Other enzyme inhibitors are poisons. For example, the poison cyanide is an irreversible enzyme inhibitor that combines with the copper and iron in the active site of the enzyme cytochrome c oxidase and blocks cellular respiration.
Tametraline, a compound synthesized in 1978 by Pfizer, was shown to be a potent NE and DA re-uptake inhibitor with animal studies. Later on a surprisingly substantial enhancement of blocking activity of 5-HT uptake was achieved by adding chlorine atoms at C-3 and C-4 to the structure of tametraline, resulting in (+)-trans-(1R,4S)-N-methyl-4-phenyl-1-aminotetralin, a potent but nonselective uptake blocker. The (+)-cis-(1S,4S)-isomer, one of four compounds diastereomers, however exhibited significantly more selective and potent 5-HT uptake inhibiting activity compared to the other three diastereomers, where the 4-phenyl ring favours attachments at 5-HT uptake sites. The compound was named sertraline (figure 8). Although sertraline appears to differ structurally from the other SSRIs, it has a phenylaminotetralin in its structure, in which the diphenylpropylamine nucleus has been forced into a stiff bicyclic ring system. Sertraline is the second most potent inhibitor of 5-HT re-uptake which has two very interesting characteristics that distinguish it i.e. sertraline's (1) inhibiting effect on DAT and NET and (2) the binding to sigma-1 (σ1) receptor in CNS. The DAT and NET inhibition is controversial because of much weaker inhibition which it has, compared to SERT inhibition. Sertraline has about 60 times more potent inhibition potential on 5-HT than either NE or DA re-uptake. It is possible that only modest inhibition of DAT and NET is needed to cause an increase in energy, motivation and concentration, specially when added to other activity such as SERT inhibition.
Vibrational spectroscopy covers a range of techniques, including conventional Fourier transform infrared (FTIR), Raman, and attenuated total reflectance (ATR) spectroscopy. These methods have been variously employed for the study of textile fibers, not only to identify the fibers themselves and their state of deterioration but also to confirm processing and dye treatment. Stabilization treatments for archaeological textiles have been laid out in field guides and reports with general guidelines but they seldom specify fiber type when discussing stabilization treatments. Tarleton & Ordoñez state “Some of these treatments utilize materials such as surfactants, lubricants, or consolidants.”
== Career == In 2008, Nazeri joined Novo Nordisk in Iran, before working in their global affairs department in Denmark. As global medical director she was in charge of the research portfolio on modern insulins aspart and semaglutide. In 2013 Nazeri became head of medical affairs in Canada, where she launched Key Opinion Leader (KOL) engagement and learning programmes within their medical affairs group. In October 2016 Nazeri was appointed as director of Novo Nordisk and worked to build partnerships and drive innovation. Nazeri has expressed concern about the lack of awareness around the health risks of diabetes mellitus type 2, especially with regards to the development of cardiovascular disease. In 2017 Nazeri urged the public to return faulty insulin cartridge holders in the NovoPen Echo and NovoPen 5 devices, which were found to break when exposed to household cleaning agents. Under her leadership, the organisation has expanded treatment options for patients with diabetes. It was reported that Novo Nordisk's insulin degludec was the most cost-effective diabetic treatment. She launched Fiasp, a new fast acting insulin, which improves blood sugar levels after meals by working twice as quickly in the bloodstream. Nazeri has contributed to Pharmaceutical Journal.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.